financetom
Business
financetom
/
Business
/
Intel Issued 'Subseasonal' H2 Revenue Guidance Amid Challenging Markets, AMD Competition, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intel Issued 'Subseasonal' H2 Revenue Guidance Amid Challenging Markets, AMD Competition, Wedbush Says
Aug 2, 2024 8:13 AM

10:45 AM EDT, 08/02/2024 (MT Newswires) -- Intel ( INTC ) provided a "subseasonal" H2 revenue guidance which it attributed to "more difficult end markets" and expected loss of market share to Advanced Micro Devices ( AMD ) in the personal computer and server segments, Wedbush said in a note emailed Friday.

The company said a nearly 400-basis-point drop in gross margin due to underutilization, competitive pricing and a faster transition to the Lunar Lake platform, which involved ramping up new capacity nodes in Ireland and shifting part content to Taiwan Semiconductor Manufacturing (TSM), Wedbush analyst Matt Bryson said in the note.

Wedbush also said that Intel ( INTC ) plans to reduce capital expenditures and operating expenses to improve financial efficiency amid the challenging market environment and suspended its dividend to preserve cash and redirect funds to investments and cost-cutting measures.

The accelerated shift towards Lunar and Meteor Lake platforms is expected to compress the financial impact of initial poor yields and reduce capital costs by limiting pilot programs, Wedbush said.

"[W]ith Intel ( INTC ) in the midst of massive technological transitions that necessarily investors have little insight into, we believe these questions will weigh on sentiment until Intel ( INTC ) can offer some more promising concrete signs of progress, bolstering confidence that Intel ( INTC ) is indeed executing to plan on its manufacturing and product initiatives," Bryson said.

Wedbush lowered its price target on Intel's ( INTC ) stock to $25 from $32.50, while reiterating its neutral rating.

Shares of the company were down over 29% in recent trading.

Price: 20.70, Change: -8.35, Percent Change: -28.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FactSet Research's Annual Subscription Value Poised to Top Q2 Consensus, RBC Says
FactSet Research's Annual Subscription Value Poised to Top Q2 Consensus, RBC Says
Mar 10, 2025
11:44 AM EDT, 03/10/2025 (MT Newswires) -- FactSet Research Systems' ( FDS ) annual subscription value is poised to top the market consensus in fiscal Q2 following the acquisition of LiquidityBook, RBC Capital Markets said Monday in a report. RBC projects Q2 ASV of $2.32 billion versus the consensus of $2.30 billion with an estimated $18 million from the LiquidityBook...
SciSparc Shares Are Soaring Monday: What's Going On?
SciSparc Shares Are Soaring Monday: What's Going On?
Mar 10, 2025
SciSparc Ltd ( SPRC ) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc ( CMND ) led to a patent application for psychedelic therapy targeting cocaine addiction. What Happened: A patent application was published by the South Korean Intellectual Property Office for a combination treatment using Clearmind’s 5-methoxy-2-aminoindane and SciSparc’s Palmitoylethanolamide for...
SenesTech's Financing Move: $1.1 Million From Warrant Exercise, New Deals Loom
SenesTech's Financing Move: $1.1 Million From Warrant Exercise, New Deals Loom
Mar 10, 2025
SenesTech, Inc. ( SNES ) shares are trading lower on Monday. The company inked deals to immediately exercise outstanding warrants for a total of 374,718 shares of common stock, originally issued on August 23, 2024, with a reduced exercise price of $2.90 per share, down from $4.35. Additionally, the company will issue new short-term warrants. The exercise of existing warrants...
BioNTech Projects 2025 Sales Weakness, Plans R&D Ramp up
BioNTech Projects 2025 Sales Weakness, Plans R&D Ramp up
Mar 10, 2025
11:44 AM EDT, 03/10/2025 (MT Newswires) -- BioNTech (BNTX) reported a decline in fourth-quarter revenue and projected full-year sales to fall again in 2025, while the German drugmaker announced plans to ramp up research and development efforts for future oncology product launches. Revenue declined to 1.19 billion euros ($1.29 billion) for the three months ended Dec. 31 from 1.48 billion...
Copyright 2023-2026 - www.financetom.com All Rights Reserved